Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

[1]  D. Ribatti,et al.  The role of monocytes-macrophages in vasculogenesis in multiple myeloma , 2009, Leukemia.

[2]  J. Mönkkönen,et al.  Zoledronic acid induces formation of a pro‐apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF‐7 cells in vitro , 2009, British journal of pharmacology.

[3]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[4]  D. Ribatti,et al.  Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. , 2008, Blood.

[5]  M. Boccadoro,et al.  Thalidomide for treatment of multiple myeloma: 10 years later. , 2008, Blood.

[6]  Udo Oppermann,et al.  Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. , 2008, Journal of medicinal chemistry.

[7]  M. Katsuki,et al.  Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells , 2008, The Journal of cell biology.

[8]  D. Ribatti,et al.  Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma , 2008, Oncogene.

[9]  D. Ribatti,et al.  Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma , 2007, Molecular Cancer Therapeutics.

[10]  H. Zhang,et al.  NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. , 2007, Histology and histopathology.

[11]  P. Richardson,et al.  The malignant clone and the bone-marrow environment. , 2007, Best practice & research. Clinical haematology.

[12]  X. Bustelo,et al.  GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  D. Ribatti,et al.  Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma , 2006, Oncogene.

[14]  P. Clézardin,et al.  Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. , 2005, Cancer research.

[15]  D. Esseltine,et al.  Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. , 2005, Blood.

[16]  K. Podar,et al.  The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.

[17]  K. Mystakidou,et al.  Prostate Cancer Presenting with Normal Serum PSA Levels and Boney Metastases Treated with Zoledronic Acid , 2005, Journal of pain & palliative care pharmacotherapy.

[18]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[19]  P. Richardson,et al.  Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib , 2004, Cancer Research.

[20]  James B. Mitchell,et al.  Nuclear Factor-κB is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma , 2004, Cancer Research.

[21]  N. Munshi,et al.  Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma , 2003, Oncogene.

[22]  D. Guidolin,et al.  Endothelial cells in the bone marrow of patients with multiple myeloma. , 2003, Blood.

[23]  D. Schenkein,et al.  A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. , 2003, Clinical lymphoma.

[24]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[25]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[26]  P. Clézardin.  The antitumor potential of bisphosphonates. , 2002, Seminars in oncology.

[27]  P. LoRusso,et al.  Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases , 2002, Journal of clinical pharmacology.

[28]  Douglas B. Evans,et al.  The function of multiple IκB : NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis , 2002, Oncogene.

[29]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[30]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[31]  W. McBride,et al.  The Proteasome in Cancer Biology and Treatment , 2001, Radiation research.

[32]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[33]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[35]  B. Durie.  Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.

[36]  K. Lyseng-Williamson,et al.  Zoledronic Acid , 2012, Drugs.

[37]  Yiwei Li,et al.  NF-kappaB: a potential target for cancer chemoprevention and therapy. , 2008, Frontiers in bioscience : a journal and virtual library.

[38]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[39]  D. Ribatti,et al.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. , 2003, Haematologica.

[40]  A. Lipton,et al.  Oral bisphosphonates , 2000, Cancer.

[41]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.